Vaderis $152M Series B and Phase 3 HEROIC

Vaderis Therapeutics, a clinical-stage biopharmaceutical company focused on rare vascular diseases, announced the closing of an oversubscribed $152 million Series B financing and the initiation of its global Phase 3 HEROIC study. The financing was co-led by Life Sciences at Goldman Sachs and TCGX, with participation from Omega Funds, Tiziana Life Sciences, Perceptive Advisors, Kalehua Capital, and existing investors Medicxi and Droia Ventures. The proceeds are expected to fund operations through potential U.S. regulatory approval of engasertib (VAD044), an investigational oral allosteric AKT inhibitor being developed for hereditary hemorrhagic telangiectasia (HHT), a rare genetic vascular disorder with no approved treatments. The Phase 3 HEROIC study is a randomized, double-blind, placebo-controlled trial evaluating once-daily oral engasertib in patients with moderate-to-severe HHT, enrolling across North America, South America, and Europe. The announcement follows publication of positive proof-of-concept and long-term extension data in The New England Journal of Medicine. The company also announced its board of directors, including representatives from Medicxi, Goldman Sachs, TCGX, Omega Funds, and independent director Rahul Ballal.